Activated Src protein tyrosine kinase is overexpressed in late-stage human ovarian cancers

Jon R. Wiener, Christopher Windham, Veronica C. Estrella, Nila U. Parikh, Peter F. Thall, Michael T. Deavers, Robert C. Bast, Gordon B. Mills, Gary E. Gallick

    Research output: Contribution to journalArticle

    153 Scopus citations

    Abstract

    Objective. The objective of this study was to determine if the Src tyrosine kinase is overexpressed and activated in late-stage human ovarian cancers. Methods. Western analysis and immune complex kinase assays were performed on a panel of human ovarian cancer cell lines and normal ovarian epithelial cell cultures, and immunohistochemical analysis for Src and activated Src were performed on a panel of late-stage human ovarian tumors. Results and conclusions. Src is overexpressed and activated in a majority of late-stage ovarian tumors as well as in a panel of cultured malignant human ovarian epithelium grown in vitro, but not in normal ovarian epithelium (NOE) or immortalized NOE. Src overexpression was found to be frequently, but not always, associated with HER-2/neu overexpression, but no statistical association between Src and Her-2/neu overexpression could be demonstrated.

    Original languageEnglish (US)
    Pages (from-to)73-79
    Number of pages7
    JournalGynecologic oncology
    Volume88
    Issue number1
    DOIs
    StatePublished - Jan 1 2003

    Keywords

    • Immuno-histochemistry
    • Monoclonal antibody
    • Ovarian cancer
    • Src
    • Tyrosine kinase
    • Yes

    ASJC Scopus subject areas

    • Oncology
    • Obstetrics and Gynecology

    Fingerprint Dive into the research topics of 'Activated Src protein tyrosine kinase is overexpressed in late-stage human ovarian cancers'. Together they form a unique fingerprint.

  • Cite this

    Wiener, J. R., Windham, C., Estrella, V. C., Parikh, N. U., Thall, P. F., Deavers, M. T., Bast, R. C., Mills, G. B., & Gallick, G. E. (2003). Activated Src protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecologic oncology, 88(1), 73-79. https://doi.org/10.1006/gyno.2002.6851